Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 38 publications
Elexacaftor-Tezacaftor-Ivacaftor for Individuals with Residual CFTR Activity: An Open-Label, Nonrandomized Clinical Trial.
Journal: Annals of the American Thoracic Society
Published: March 06, 2026
Elexacaftor-tezacaftor-ivacaftor for individuals with residual CFTR activity: an open-label, nonrandomized clinical trial.
Journal: Annals of the American Thoracic Society
Published: March 06, 2026
Endocrine Care During Transition in Emerging Adults With Cystic Fibrosis: A Single Center Retrospective Study.
Journal: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Published: November 13, 2025
The role of sweat chloride in determining CFTR protein restoration in people with cystic fibrosis.
Journal: The Lancet. Respiratory medicine
Published: August 29, 2025
Evaluating Georgia's Cystic Fibrosis Newborn Screening Algorithm to Inform Improvement Recommendations.
Journal: International journal of neonatal screening
Published: June 29, 2025
CFTR Variant Frequencies and Newborn Screening Panel Performance in the Diverse CF Population Receiving Care in the State of Georgia.
Journal: International journal of neonatal screening
Published: June 20, 2025
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One F508del Allele: A Phase 3 Open-Label Extension Study.
Journal: American journal of respiratory and critical care medicine
Published: April 10, 2025
Improving Modulator Management and Side Effect Screening: A CF Learning Network Innovation Lab.
Journal: Pediatric pulmonology
Published: February 14, 2025
Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.
Journal: The Lancet. Respiratory medicine
Published: October 25, 2024
Impact of Discontinuing Both Hypertonic Saline and Dornase Alfa after Elexacaftor-Tezacaftor-Ivacaftor in Cystic Fibrosis.
Journal: Annals of the American Thoracic Society
Published: July 23, 2024
Validation of the Integrated Palliative Care Outcome Scale (IPOS) in adults with cystic fibrosis.
Journal: Pediatric pulmonology
Published: March 28, 2024
Last Updated: 09/26/2026